Profit Margin (Quarterly) Chart

Historical Profit Margin (Quarterly) Data

View and export this data back to 2006. Start Trial.
Date Value
June 30, 2024 -719.6%
March 31, 2024 -824.0%
December 31, 2023
September 30, 2023
June 30, 2023
March 31, 2023 -6.30K%
December 31, 2022 -3.80K%
September 30, 2022 -3.14K%
June 30, 2022 -3.34K%
March 31, 2022 -2.24K%
December 31, 2021 -1.96K%
September 30, 2021 -2.61K%
June 30, 2021 -1.78K%
March 31, 2021 -1.31K%
December 31, 2020 -1.35K%
September 30, 2020 -1.06K%
June 30, 2020 -812.7%
March 31, 2020 -2.01K%
December 31, 2019 -4.89K%
September 30, 2019 -884.8%
June 30, 2019 -588.4%
March 31, 2019 -1.82K%
December 31, 2018 -1.38K%
September 30, 2018 -3.47K%
June 30, 2018 -839.6%
Date Value
March 31, 2018 -3.82K%
December 31, 2017 -2.45K%
September 30, 2017 -908.1%
June 30, 2017 -930.7%
March 31, 2017 -645.7%
December 31, 2016 -461.0%
September 30, 2016 -331.9%
June 30, 2016 -1.33K%
March 31, 2016 -2.25K%
December 31, 2015 -3.09K%
September 30, 2015 -949.5%
June 30, 2015 -816.3%
March 31, 2015 -905.9%
December 31, 2014 -678.4%
September 30, 2014 -1.06K%
June 30, 2014 -618.5%
March 31, 2014 -762.8%
December 31, 2013 -969.3%
September 30, 2013 -848.1%
June 30, 2013 -461.1%
March 31, 2013 -348.1%
December 31, 2012 -681.2%
September 30, 2012 -1.15K%
June 30, 2012 -861.1%
March 31, 2012 73.34%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Agenus, Inc. -1.64%
Amgen, Inc. 23.59%
Anika Therapeutics, Inc. 10.15%
BioCryst Pharmaceuticals, Inc. 35.92%
Imunon, Inc. --